Onco-Innovations has made significant progress in scaling up and optimizing the production of key precursor materials A83 and B4 for its ONC010 oncology drug program. This work supports the manufacturing strategy for future GMP production and regulatory approval, aiming to advance ONC010 toward clinical trials in Australia. The company, working with Dalton Pharma Services, has improved process reproducibility and purity, strengthening the foundation for clinical and commercial development. These advancements mark a crucial step in preparing ONC010 for first-in-human studies.
Li Auto has integrated Arteris' FlexNoC 5 network-on-chip IP and Magillem software into its proprietary autonomous driving SoCs for the new L9 Livis SUV. This technology supports AI data movement and integration, enabling the vehicle to perform 2,560...
Arteris, Inc. announced its system IP technology is adopted by Li Auto for its new L9 Livis flagship SUV, integrating the Mach M100 autonomous driving SoC. This collaboration enhances AI data movement and system efficiency, meeting high performance, ...
Durantic, founded by former Meta and Hudson River Trading engineers, has launched a managed infrastructure layer to operate AI workloads across diverse GPU environments. The company addresses the growing complexity of AI infrastructure, which spans h...
Viavi Solutions announced a public offering of 11.1 million shares at $45 each, aiming to raise about $500 million before fees. The proceeds will primarily repay $450 million of Term Loan B debt, with any remaining funds used for working capital or g...
Singapore has signed agreements with OpenAI and Google to enhance its AI ecosystem and accelerate AI use in public services, healthcare, education, and enterprise. OpenAI will invest over 300 million Singapore dollars to establish its first overseas ...
